|
WO2021022132A1
|
|
Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hosts
|
|
WO2021011435A1
|
|
Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
|
|
WO2020150263A1
|
|
Selectin or galectin antagonists for treating cytokine release syndrome and crs-induced neurotoxicity
|
|
US2013261070A1
|
|
Anti-epileptogenic agents
|
|
CA2227013A1
|
|
Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
|
|
US6121233A
|
|
Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
|
